ERBB2 and breast cancer: Studies have found that low plasma adiponectin levels will increase the risk of breast cancer in premenopausal and postmenopausal women, especially in luminal breast cancer and postmenopausal HER-2-enriched breast cancer, which shows that adiponectin has an anti-breast cancer effect (58, 59).